[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombotic-thrombocytopenic-purpura-acquired\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombotic-thrombocytopenic-purpura-acquired":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100632458",false,"NCT07513948","Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura","DarTTP: an Observational, International, Multicentric Study on Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","DarTTP","Inclusion Criteria:\n\n* patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity \\\u003C10% with anti-ADAMTS13 antibodies detected);\n* aged ≥ 18 years;\n* male and female patients;\n* treated with daratumumab for iTTP.\n\nExclusion Criteria:\n\n* patients unwilling or unable to provide their informed consent;\n* follow-up \\\u003C 6 months after daratumumab administration.","ALL","18 Years","99 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.",[25],"Thrombotic Thrombocytopenic Purpura, Acquired",[27,28,29],"daratumumab","thrombotic thrombocytopenic purpura","ADAMTS13","RECRUITING","2026-04-13",{"date":33,"type":34},"2026-04-14","ACTUAL",{"date":36,"type":34},"2025-10-01",{"date":38,"type":21},"2026-08",{"name":40,"class":41},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100587426","NCT06928233","Association of TNFAIP3 With Immune-mediated TTP","Association of the TNFAIP3 Genomic Locus With Immune-mediated TTP","A20iTTP","Patients:\n\nInclusion Criteria:\n\n* Diagnosis of iTTP\n* Above 12 years of age\n* Caucasian, Italian origin\n* Written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients who do not meet the above-listed criteria will be excluded from participation in the study.\n\nControls will be healthy Italian volunteers of Caucasian ethnicity, with no history of thrombotic thrombocytopenic purpura, frequency-matched to cases by age and sex, and who have provided written informed consent to participate in the study.",true,"12 Years",{"count":53,"type":21},400,"INTERVENTIONAL",[56],"NA","This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.",[25],[60,61,62],"A20","iTTP","TNFAIP3","2026-03-26",{"date":65,"type":34},"2026-03-27",{"date":67,"type":34},"2025-04-07",{"date":69,"type":21},"2026-04",{"name":40,"class":41},""]